SEC For	m 4																	
FORM 4 UNITED S				STATE	ATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See				Filed p	NT OF CHANGES IN BENEFICIAL OWNER d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										3235-0287 0.5			
1. Name and Address of Reporting Person <sup>*</sup> Mills C Randal					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>AZIYO BIOLOGICS, INC.</u> [ AZYO ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle C/O AZIYO BIOLOGICS, INC. 12510 PROSPERITY DRIVE, SUITE 370			(Middle)		3. Date of Earliest Transaction (Month/Day/Year) X Officer (give the below)   06/21/2022 Interim I								ve title Other (specify below) n President and CEO					
(Street) SILVER MD			20904	4	. If Ame	endment, I	Date (	of Original Filed (Month/Day/Year)			Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	State)	(Zip)									Person						
1. Title of Security (Instr. 3) 2. Transa Date				2. Transacti	action 2A. Deemed Execution Date if any (Month/Day/Yea			a, 3. Transact Code (Ins	Transaction Code (Instr. 8)			5. Amoun Securities Beneficia Owned Fo Reported	s Ily ollowing	6. Own Form: (D) or I (I) (Inst	Direct I Indirect E tr. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code \					(D)		Transacti (Instr. 3 a							
			Table II - D (e					uired, Dis s, options				Owned						
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date ecurity or Exercise (Month/Day/Year)		3A. Deemed Execution Date if any (Month/Day/Ye	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(0)				
Stock Option (Right to Buy)	<b>\$</b> 6.39	06/21/2022		Α		273,767		(1)	06/20/2032	Class A Common Stock	273,767	\$0	273,76	7	D			
Stock Option (Right to Buy)	<b>\$</b> 6.39	06/21/2022		A		182,511		(2)	06/20/2032	Class A Common Stock	182,511	\$0	182,51	1	D			

## Explanation of Responses:

1. The option vests and becomes exercisable as to one-third of the underlying shares upon the day following the expiration of the Interim Period (as defined in the Reporting Person's Employment Agreement dated June 21, 2022). The remaining two-thirds of the underlying shares vest and become exercisable, with respect to 25% of such shares, on June 21, 2023, and, with respect to 75% of such shares, in twelve equal quarterly installments thereafter, beginning on September 21, 2023, subject to the Reporting Person's continuous employment with the Issuer through the applicable vesting date.

2. The option vests and becomes exercisable in four equal installments upon the Issuer's achievement of a share price equal to or greater than \$12.50, \$17.00, \$25.00 and \$37.00, in each case determined based on twenty consecutive days of trading at or above the applicable threshold, subject to the Reporting Person's continuous employment with the Issuer through the applicable vesting date.

/s/ Jeffrey Hamet, Attorney-in- Fact for C Randal Mills	06/23/2022
** Signature of Departing Derson	Data

\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.